Trials / Terminated
TerminatedNCT01678924
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-214868 | AGN-214868 given as injections into the area of pain on Day 1. |
| DRUG | AGN-214868 Placebo (Vehicle) | AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-05-01
- Completion
- 2015-09-01
- First posted
- 2012-09-05
- Last updated
- 2020-01-07
- Results posted
- 2020-01-07
Locations
69 sites across 4 countries: United States, Austria, Germany, Poland
Source: ClinicalTrials.gov record NCT01678924. Inclusion in this directory is not an endorsement.